{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["infectious diseases", "natural products", "pan-inhibitor", "virtual drug screening"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35337106", "DateRevised": {"Year": "2022", "Month": "03", "Day": "29"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "03", "Day": "03"}], "Language": ["eng"], "ELocationID": ["308", "10.3390/ph15030308"], "Journal": {"ISSN": "1424-8247", "JournalIssue": {"Volume": "15", "Issue": "3", "PubDate": {"Year": "2022", "Month": "Mar", "Day": "03"}}, "Title": "Pharmaceuticals (Basel, Switzerland)", "ISOAbbreviation": "Pharmaceuticals (Basel)"}, "ArticleTitle": "In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library.", "Abstract": {"AbstractText": ["The main protease (M<sup>pro</sup> or 3CL<sup>pro</sup>) in coronaviruses represents a promising specific drug target as it is essential for the cleavage of the virus polypeptide and has a unique cleavage site that does not exist in human host proteases. In this study, we explored potential natural pan-coronavirus drugs using in vitro and in silico approaches and three coronavirus main proteases as treatment targets. The PyRx program was used to screen 39,442 natural-product-like compounds from the ZINC database and 121 preselected phytochemicals from medicinal plants with known antiviral activity. After assessment with Lipinski's rule of five, molecular docking was performed for the top 33 compounds of both libraries. Enzymatic assays were applied for the top candidates from both in silico approaches to test their ability to inhibit SARS-CoV-2 M<sup>pro</sup>. The four compounds (hypericin, rosmarinic acid, isorhamnetin, and luteolin) that most efficiently inhibited SARS-CoV-2 M<sup>pro</sup> in vitro were further tested for their efficacy in inhibiting M<sup>pro</sup> of SARS-CoV-1 and MERS-CoV. Microscale thermophoresis was performed to determine dissociation constant (Kd) values to validate the binding of these active compounds to recombinant M<sup>pro</sup> proteins of SARS-CoV-2, SARS-CoV-1, and MERS-CoV. The cytotoxicity of hypericin, rosmarinic acid, isorhamnetin, and luteolin was assessed in human diploid MRC-5 lung fibroblasts using the resazurin cell viability assay to determine their therapeutic indices. Sequence alignment of M<sup>pro</sup> of SARS-CoV-2 demonstrated 96.08%, 50.83%, 49.17%, 48.51%, 44.04%, and 41.06% similarity to M<sup>pro</sup> of other human-pathogenic coronaviruses (SARS-CoV-1, MERS-CoV, HCoV-NL63, HCoV-OC43, HCoV-HKU1, and HCoV-229E, respectively). Molecular docking showed that 12 out of 121 compounds were bound to SARS-CoV-2 M<sup>pro</sup> at the same binding site as the control inhibitor, GC376. Enzyme inhibition assays revealed that hypericin, rosmarinic acid, isorhamnetin, and luteolin inhibited M<sup>pro</sup> of SARS-CoV-2, while hypericin and isorhamnetin inhibited M<sup>pro</sup> of SARS-CoV-1; hypericin showed inhibitory effects toward M<sup>pro</sup> of MERS-CoV. Microscale thermophoresis confirmed the binding of these compounds to M<sup>pro</sup> with high affinity. Resazurin assays showed that rosmarinic acid and luteolin were not cytotoxic toward MRC-5 cells, whereas hypericin and isorhamnetin were slightly cytotoxic. We demonstrated that hypericin represents a potential novel pan-anti-coronaviral agent by binding to and inhibiting M<sup>pro</sup> of several human-pathogenic coronaviruses. Moreover, isorhamnetin showed inhibitory effects toward SARS-CoV-2 and SARS-CoV-1 M<sup>pro</sup>, indicating that this compound may have some pan-coronaviral potential. Luteolin had inhibitory effects against SARS-CoV-2 M<sup>pro</sup>."]}, "AuthorList": [{"Identifier": ["0000-0001-9454-3599"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg5, 55128 Mainz, Germany."}], "LastName": "Shahhamzehei", "ForeName": "Nasim", "Initials": "N"}, {"Identifier": ["0000-0002-9186-2516"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg5, 55128 Mainz, Germany."}], "LastName": "Abdelfatah", "ForeName": "Sara", "Initials": "S"}, {"Identifier": ["0000-0002-2637-1681"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg5, 55128 Mainz, Germany."}], "LastName": "Efferth", "ForeName": "Thomas", "Initials": "T"}], "GrantList": [{"GrantID": "0", "Agency": "donation of Marc Strobel, CVC Capital Partners, Frankfurt a. M., Germany", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmaceuticals (Basel)", "NlmUniqueID": "101238453", "ISSNLinking": "1424-8247"}, "CoiStatement": "The authors declare that there is no conflict of interest. The stipend, donation, and provision of compounds had no influence on the design, performance, or evaluation of results."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "V\u2019Kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155\u2013170. doi: 10.1038/s41579-020-00468-6.", "ArticleIdList": ["10.1038/s41579-020-00468-6", "PMC7592455", "33116300"]}, {"Citation": "Park S.E. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19) Korean J. Pediatr. 2020;63:119\u2013124. doi: 10.3345/cep.2020.00493.", "ArticleIdList": ["10.3345/cep.2020.00493", "PMC7170784", "32252141"]}, {"Citation": "Totura A.L., Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin. Drug Discov. 2019;14:397\u2013412. doi: 10.1080/17460441.2019.1581171.", "ArticleIdList": ["10.1080/17460441.2019.1581171", "PMC7103675", "30849247"]}, {"Citation": "Xia S., Yan L., Xu W., Agrawal A.S., Algaissi A., Tseng C.-T.K., Wang Q., Du L., Tan W., Wilson I.A., et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci. Adv. 2019;5:eaav4580. doi: 10.1126/sciadv.aav4580.", "ArticleIdList": ["10.1126/sciadv.aav4580", "PMC6457931", "30989115"]}, {"Citation": "Menachery V.D., Yount B.L., Jr., Debbink K., Agnihothram S., Gralinski L.E., Plante J.A., Graham R.L., Scobey T., Ge X.-Y., Donaldson E.F., et al. A SARS-like Cluster of Circulating Bat Coronaviruses Shows Potential for Human Emergence. Nat. Med. 2015;21:1508\u20131513. doi: 10.1038/nm.3985.", "ArticleIdList": ["10.1038/nm.3985", "PMC4797993", "26552008"]}, {"Citation": "Xiao K., Zhai J., Feng Y., Zhou N., Zhang X., Zou J.-J., Li N., Guo Y., Li X., Shen X., et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature. 2020;583:286\u2013289. doi: 10.1038/s41586-020-2313-x.", "ArticleIdList": ["10.1038/s41586-020-2313-x", "32380510"]}, {"Citation": "Wacharapluesadee S., Tan C.W., Maneeorn P., Duengkae P., Zhu F., Joyjinda Y., Kaewpom T., Ni Chia W., Ampoot W., Lim B.L., et al. Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia. Nat. Commun. 2021;12:972. doi: 10.1038/s41467-021-21240-1.", "ArticleIdList": ["10.1038/s41467-021-21240-1", "PMC7873279", "33563978"]}, {"Citation": "Grange Z.L., Goldstein T., Johnson C.K., Anthony S., Gilardi K., Daszak P., Olival K.J., O\u2019Rourke T., Murray S., Olson S.H., et al. Ranking the risk of animal-to-human spillover for newly discovered viruses. Proc. Natl. Acad. Sci. USA. 2021;118:e2002324118. doi: 10.1073/pnas.2002324118.", "ArticleIdList": ["10.1073/pnas.2002324118", "PMC8053939", "33822740"]}, {"Citation": "Johnson C.K., Hitchens P.L., Pandit P.S., Rushmore J., Evans T.S., Young C.C.W., Doyle M.M. Global shifts in mammalian population trends reveal key predictors of virus spillover risk. Proc. R. Soc. B Biol. Sci. 2020;287:20192736. doi: 10.1098/rspb.2019.2736.", "ArticleIdList": ["10.1098/rspb.2019.2736", "PMC7209068", "32259475"]}, {"Citation": "Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395:565\u2013574. doi: 10.1016/S0140-6736(20)30251-8.", "ArticleIdList": ["10.1016/S0140-6736(20)30251-8", "PMC7159086", "32007145"]}, {"Citation": "Harrison A.G., Lin T., Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020;41:1100\u20131115. doi: 10.1016/j.it.2020.10.004.", "ArticleIdList": ["10.1016/j.it.2020.10.004", "PMC7556779", "33132005"]}, {"Citation": "Hu B., Guo H., Zhou P., Shi Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141\u2013154. doi: 10.1038/s41579-020-00459-7.", "ArticleIdList": ["10.1038/s41579-020-00459-7", "PMC7537588", "33024307"]}, {"Citation": "Kneller D.W., Phillips G., O\u2019Neill H.M., Jedrzejczak R., Stols L., Langan P., Joachimiak A., Coates L., Kovalevsky A. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat. Commun. 2020;11:3202. doi: 10.1038/s41467-020-16954-7.", "ArticleIdList": ["10.1038/s41467-020-16954-7", "PMC7314768", "32581217"]}, {"Citation": "Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C., et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289\u2013293. doi: 10.1038/s41586-020-2223-y.", "ArticleIdList": ["10.1038/s41586-020-2223-y", "32272481"]}, {"Citation": "Ma C., Sacco M.D., Hurst B., Townsend J.A., Hu Y., Szeto T., Zhang X., Tarbet B., Marty M., Chen Y., et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;30:678\u2013692. doi: 10.1038/s41422-020-0356-z.", "ArticleIdList": ["10.1038/s41422-020-0356-z", "PMC7294525", "32541865"]}, {"Citation": "Ullrich S., Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg. Med. Chem. Lett. 2020;30:127377. doi: 10.1016/j.bmcl.2020.127377.", "ArticleIdList": ["10.1016/j.bmcl.2020.127377", "PMC7331567", "32738988"]}, {"Citation": "Hilgenfeld R. From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281:4085\u20134096. doi: 10.1111/febs.12936.", "ArticleIdList": ["10.1111/febs.12936", "PMC7163996", "25039866"]}, {"Citation": "Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Drug Delivery Reviews Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001;46:3\u201326. doi: 10.1016/S0169-409X(00)00129-0.", "ArticleIdList": ["10.1016/S0169-409X(00)00129-0", "11259830"]}, {"Citation": "Musarra-Pizzo M., Pennisi R., Ben-Amor I., Mandalari G., Sciortino M. Antiviral Activity Exerted by Natural Products against Human Viruses. Viruses. 2021;13:828. doi: 10.3390/v13050828.", "ArticleIdList": ["10.3390/v13050828", "PMC8147851", "34064347"]}, {"Citation": "Koehn F.E., Carter G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005;4:206\u2013220. doi: 10.1038/nrd1657.", "ArticleIdList": ["10.1038/nrd1657", "15729362"]}, {"Citation": "Kadioglu O., Saeed M., Greten H.J., Efferth T. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning. Comput. Biol. Med. 2021;133:104359. doi: 10.1016/j.compbiomed.2021.104359.", "ArticleIdList": ["10.1016/j.compbiomed.2021.104359", "PMC8008812", "33845270"]}, {"Citation": "Miskovsky P. Hypericin\u2014A New Antiviral and Antitumor Photosensitizer: Mechanism of Action and Interaction with Biological Macromolecules. Curr. Drug Targets. 2002;3:55\u201384. doi: 10.2174/1389450023348091.", "ArticleIdList": ["10.2174/1389450023348091", "11899265"]}, {"Citation": "Fukuchi K., Okudaira N., Adachi K., Odai-Ide R., Watanabe S., Ohno H., Yamamoto M., Kanamoto T., Terakubo S., Nakashima H., et al. Antiviral and Antitumor Activity of Licorice Root Extracts. In Vivo. 2016;30:777\u2013786. doi: 10.21873/invivo.10994.", "ArticleIdList": ["10.21873/invivo.10994", "27815461"]}, {"Citation": "Jennings M., Parks R. Curcumin as an Antiviral Agent. Viruses. 2020;12:1242. doi: 10.3390/v12111242.", "ArticleIdList": ["10.3390/v12111242", "PMC7693600", "33142686"]}, {"Citation": "V\u00e1zquez-Calvo A., de Oya N.J., Martin-Acebes M.A., Garcia-Moruno E., Saiz J.-C. Antiviral Properties of the Natural Polyphenols Delphinidin and Epigallocatechin Gallate against the Flaviviruses West Nile Virus, Zika Virus, and Dengue Virus. Front. Microbiol. 2017;8:1314. doi: 10.3389/fmicb.2017.01314.", "ArticleIdList": ["10.3389/fmicb.2017.01314", "PMC5504193", "28744282"]}, {"Citation": "Cataneo A.H.D., Kuczera D., Koishi A.C., Zanluca C., Silveira G.F., De Arruda T.B., Suzukawa A.A., Bortot L.O., Dias-Baruffi M., Verri W.A., Jr., et al. The citrus flavonoid naringenin impairs the in vitro infection of human cells by Zika virus. Sci. Rep. 2019;9:16348. doi: 10.1038/s41598-019-52626-3.", "ArticleIdList": ["10.1038/s41598-019-52626-3", "PMC6841724", "31705028"]}, {"Citation": "Kai H., Obuchi M., Yoshida H., Watanabe W., Tsutsumi S., Park Y.K., Matsuno K., Yasukawa K., Kurokawa M. In vitro and in vivo anti-influenza virus activities of flavonoids and related compounds as components of Brazilian propolis (AF-08) J. Funct. Foods. 2014;8:214\u2013223. doi: 10.1016/j.jff.2014.03.019.", "ArticleIdList": ["10.1016/j.jff.2014.03.019"]}, {"Citation": "Cheng S.-C., Chang G.-G., Chou C.-Y. Mutation of Glu-166 Blocks the Substrate-Induced Dimerization of SARS Coronavirus Main Protease. Biophys. J. 2010;98:1327\u20131336. doi: 10.1016/j.bpj.2009.12.4272.", "ArticleIdList": ["10.1016/j.bpj.2009.12.4272", "PMC2849084", "20371333"]}, {"Citation": "Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science. 2020;368:409\u2013412. doi: 10.1126/science.abb3405.", "ArticleIdList": ["10.1126/science.abb3405", "PMC7164518", "32198291"]}, {"Citation": "Tomar S., Johnston M.L., John S.E.S., Osswald H.L., Nyalapatla P.R., Paul L.N., Ghosh A.K., Denison M.R., Mesecar A.D. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): Implications for Nsp5 Regulation and the Development of Antivirals. J. Biol. Chem. 2015;290:19403\u201319422. doi: 10.1074/jbc.M115.651463.", "ArticleIdList": ["10.1074/jbc.M115.651463", "PMC4528106", "26055715"]}, {"Citation": "Ho B.-L., Cheng S.-C., Shi L., Wang T.-Y., Ho K.-I., Chou C.-Y. Critical Assessment of the Important Residues Involved in the Dimerization and Catalysis of MERS Coronavirus Main Protease. PLoS ONE. 2015;10:e0144865. doi: 10.1371/journal.pone.0144865.", "ArticleIdList": ["10.1371/journal.pone.0144865", "PMC4682845", "26658006"]}, {"Citation": "Khan S.A., Zia K., Ashraf S., Uddin R., Ul-Haq Z. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J. Biomol. Struct. Dyn. 2021;39:2607\u20132616. doi: 10.1080/07391102.2020.1751298.", "ArticleIdList": ["10.1080/07391102.2020.1751298", "32238094"]}, {"Citation": "Lu I.-L., Mahindroo N., Liang P.-H., Peng Y.-H., Kuo C.-J., Tsai K.-C., Hsieh H.-P., Chao Y.-S., Wu S.-Y. Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Main Protease. J. Med. Chem. 2006;49:5154\u20135161. doi: 10.1021/jm060207o.", "ArticleIdList": ["10.1021/jm060207o", "16913704"]}, {"Citation": "Birt D.F., Widrlechner M.P., Hammer K.D.P., Hillwig M.L., Wei J., Kraus G.A., Murphy P.A., McCoy J.A., Wurtele E.S., Neighbors J.D., et al. Hypericum in Infection: Identification of Anti-Viral and Anti-Inflammatory Constituents. Pharm. Biol. 2009;47:774\u2013782. doi: 10.1080/13880200902988645.", "ArticleIdList": ["10.1080/13880200902988645", "PMC2774925", "19907671"]}, {"Citation": "Chen H., Feng R., Muhammad I., Abbas G., Zhang Y., Ren Y., Huang X., Zhang R., Diao L., Wang X., et al. Protective effects of hypericin against infectious bronchitis virus induced apoptosis and reactive oxygen species in chicken embryo kidney cells. Poult. Sci. 2019;98:6367\u20136377. doi: 10.3382/ps/pez465.", "ArticleIdList": ["10.3382/ps/pez465", "PMC7107269", "31399732"]}, {"Citation": "Shih C.-M., Wu C.-H., Wu W.-J., Hsiao Y.-M., Ko J.-L. Hypericin inhibits hepatitis C virus replication via deacetylation and down-regulation of heme oxygenase-1. Phytomedicine. 2018;46:193\u2013198. doi: 10.1016/j.phymed.2017.08.009.", "ArticleIdList": ["10.1016/j.phymed.2017.08.009", "30097118"]}, {"Citation": "Jacobson J.M., Feinman L., Liebes L., Ostrow N., Koslowski V., Tobia A., Cabana B.E., Lee D.-H., Spritzler J., Prince A.M. Pharmacokinetics, Safety, and Antiviral Effects of Hypericin, a Derivative of St. John\u2019s Wort Plant, in Patients with Chronic Hepatitis C Virus Infection. Antimicrob. Agents Chemother. 2001;45:517\u2013524. doi: 10.1128/AAC.45.2.517-524.2001.", "ArticleIdList": ["10.1128/AAC.45.2.517-524.2001", "PMC90321", "11158749"]}, {"Citation": "Lavie G., Valentine F., Levin B., Mazur Y., Gallo G., Lavie D., Weiner D., Meruelo D. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc. Natl. Acad. Sci. USA. 1989;86:5963\u20135967. doi: 10.1073/pnas.86.15.5963.", "ArticleIdList": ["10.1073/pnas.86.15.5963", "PMC297751", "2548193"]}, {"Citation": "Xu Y. Raman spectroscopic study on structure of human immu-nodeficiency virus (HIV) and hypericin-induced photosen-sitive damage of HIV. Sci. China Ser. C Life Sci. 2005;48:117. doi: 10.1360/04yc0015.", "ArticleIdList": ["10.1360/04yc0015", "15986884"]}, {"Citation": "Gulick R.M., McAuliffe V., Holden-Wiltse J., Crumpacker C., Liebes L., Stein D.S., Meehan P., Hussey S., Forcht J., Valentine F.T. Phase I Studies of Hypericin, the Active Compound in St. John\u2019s Wort, as an Antiretroviral Agent in HIV-Infected Adults: AIDS Clinical Trials Group Protocols 150 and 258. Ann. Intern. Med. 1999;130:510\u2013514. doi: 10.7326/0003-4819-130-6-199903160-00015.", "ArticleIdList": ["10.7326/0003-4819-130-6-199903160-00015", "10075619"]}, {"Citation": "Zhang Y., Chen H., Zou M., Oerlemans R., Shao C., Ren Y., Zhang R., Huang X., Li G., Cong Y. Hypericin Inhibit Alpha-Coronavirus Replication by Targeting 3CL Protease. Viruses. 2021;13:1825. doi: 10.3390/v13091825.", "ArticleIdList": ["10.3390/v13091825", "PMC8473218", "34578406"]}, {"Citation": "Pitsillou E., Liang J., Karagiannis C., Ververis K., Darmawan K.K., Ng K., Hung A., Karagiannis T.C. Interaction of small molecules with the SARS-CoV-2 main protease in silico and in vitro validation of potential lead compounds using an enzyme-linked immunosorbent assay. Comput. Biol. Chem. 2020;89:107408. doi: 10.1016/j.compbiolchem.2020.107408.", "ArticleIdList": ["10.1016/j.compbiolchem.2020.107408", "PMC7583591", "33137690"]}, {"Citation": "Dellafiora L., Galaverna G., Cruciani G., Dall\u2019Asta C., Bruni R. On the Mechanism of Action of Anti-Inflammatory Activity of Hypericin: An In Silico Study Pointing to the Relevance of Janus Kinases Inhibition. Molecules. 2018;23:3058. doi: 10.3390/molecules23123058.", "ArticleIdList": ["10.3390/molecules23123058", "PMC6321526", "30467287"]}, {"Citation": "Zhang K., Gao S., Guo J., Ni G., Chen Z., Li F., Zhu X., Wen Y., Guo Y. Hypericin-photodynamic therapy inhibits proliferation and induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes cell line MH7A. Iran. J. Basic Med. Sci. 2018;21:130\u2013137. doi: 10.22038/IJBMS.2018.23871.5991.", "ArticleIdList": ["10.22038/IJBMS.2018.23871.5991", "PMC5811751", "29456809"]}, {"Citation": "Perinbam K., Mahendrakumar M., Seeni S. Hypericin, an anthraquinone derivative of Hypericum hookerianum wight and Arn. (Hypericaceae) of Palni Hills, South India, exhibits anti-inflammatory property in lipopolysaccharide\u2014stimulated raw 264.7 macrophages. Pharmacogn. Mag. 2018;14:378. doi: 10.4103/pm.pm_485_17.", "ArticleIdList": ["10.4103/pm.pm_485_17"]}, {"Citation": "Levsh O., Pluskal T., Carballo V., Mitchell A.J., Weng J.-K. Independent evolution of rosmarinic acid biosynthesis in two sister families under the Lamiids clade of flowering plants. J. Biol. Chem. 2019;294:15193\u201315205. doi: 10.1074/jbc.RA119.010454.", "ArticleIdList": ["10.1074/jbc.RA119.010454", "PMC6802498", "31481469"]}, {"Citation": "Tsukamoto Y., Ikeda S., Uwai K., Taguchi R., Chayama K., Sakaguchi T., Narita R., Yao W.-L., Takeuchi F., Otakaki Y., et al. Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction. PLoS ONE. 2018;13:e0197664. doi: 10.1371/journal.pone.0197664.", "ArticleIdList": ["10.1371/journal.pone.0197664", "PMC5962091", "29782545"]}, {"Citation": "Mahalapbutr P., Sangkhawasi M., Kammarabutr J., Chamni S., Rungrotmongkol T. Rosmarinic Acid as a Potent Influenza Neuraminidase Inhibitor: In Vitro and In Silico Study. Curr. Top. Med. Chem. 2020;20:2046\u20132055. doi: 10.2174/1568026619666191118110155.", "ArticleIdList": ["10.2174/1568026619666191118110155", "31738149"]}, {"Citation": "Hsieh C.-F., Jheng J.-R., Lin G.-H., Chen Y.-L., Ho J.-Y., Liu C.-J., Hsu K.-Y., Chen Y.-S., Chan Y.F., Yu H.-M., et al. Rosmarinic acid exhibits broad anti-enterovirus A71 activity by inhibiting the interaction between the five-fold axis of capsid VP1 and cognate sulfated receptors. Emerg. Microbes Infect. 2020;9:1194\u20131205. doi: 10.1080/22221751.2020.1767512.", "ArticleIdList": ["10.1080/22221751.2020.1767512", "PMC7448925", "32397909"]}, {"Citation": "Elebeedy D., Elkhatib W.F., Kandeil A., Ghanem A., Kutkat O., Alnajjar R., Saleh M.A., El Maksoud A.I.A., Badawy I., Al-Karmalawy A.A. Anti-SARS-CoV-2 activities of tanshinone IIA, carnosic acid, rosmarinic acid, salvianolic acid, baicalein, and glycyrrhetinic acid between computational and in vitro insights. RSC Adv. 2021;11:29267\u201329286. doi: 10.1039/D1RA05268C.", "ArticleIdList": ["10.1039/D1RA05268C"]}, {"Citation": "Jiang K., Ma X., Guo S., Zhang T., Zhao G., Wu H., Wang X., Deng G. Anti-inflammatory Effects of Rosmarinic Acid in Lipopolysaccharide-Induced Mastitis in Mice. Inflammation. 2017;41:437\u2013448. doi: 10.1007/s10753-017-0700-8.", "ArticleIdList": ["10.1007/s10753-017-0700-8", "29204872"]}, {"Citation": "Jin B.-R., Chung K.-S., Cheon S.-Y., Lee M., Hwang S., Hwang S.N., Rhee K.-J., An H.-J. Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-\u03baB and STAT3 activation. Sci. Rep. 2017;7:srep46252. doi: 10.1038/srep46252.", "ArticleIdList": ["10.1038/srep46252", "PMC5382778", "28383063"]}, {"Citation": "Luo C., Zou L., Sun H., Peng J., Gao C., Bao L., Ji R., Jin Y., Sun S. A Review of the Anti-Inflammatory Effects of Rosmarinic Acid on Inflammatory Diseases. Front. Pharmacol. 2020;11:153. doi: 10.3389/fphar.2020.00153.", "ArticleIdList": ["10.3389/fphar.2020.00153", "PMC7059186", "32184728"]}, {"Citation": "Gong G., Guan Y.-Y., Zhang Z.-L., Rahman K., Wang S.-J., Zhou S., Luan X., Zhang H. Isorhamnetin: A review of pharmacological effects. Biomed. Pharmacother. 2020;128:110301. doi: 10.1016/j.biopha.2020.110301.", "ArticleIdList": ["10.1016/j.biopha.2020.110301", "32502837"]}, {"Citation": "Haghi G., Safaei A., Ghomi J.S. Identification and determination of flavonoids in leaf, dried aqueous and dried hydroalcoholic extract of Artemisia absinthium by HPLC. Iran. J. Basic Med. Sci. 2004;3:89\u201390."}, {"Citation": "Dayem A.A., Choi H.Y., Kim Y.B., Cho S.-G. Antiviral Effect of Methylated Flavonol Isorhamnetin against Influenza. PLoS ONE. 2015;10:e0121610. doi: 10.1371/journal.pone.0121610.", "ArticleIdList": ["10.1371/journal.pone.0121610", "PMC4373826", "25806943"]}, {"Citation": "Zhan Y., Ta W., Tang W., Hua R., Wang J., Wang C., Lu W. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro. Drug Dev. Res. 2021;82:1124\u20131130. doi: 10.1002/ddr.21815.", "ArticleIdList": ["10.1002/ddr.21815", "PMC8251057", "33847382"]}, {"Citation": "Dou W., Zhang J., Li H., Kortagere S., Sun K., Ding L., Ren G., Wang Z., Mani S. Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway. J. Nutr. Biochem. 2014;25:923\u2013933. doi: 10.1016/j.jnutbio.2014.04.006.", "ArticleIdList": ["10.1016/j.jnutbio.2014.04.006", "PMC4125479", "24913217"]}, {"Citation": "Imran M., Rauf A., Abu-Izneid T., Nadeem M., Shariati M.A., Khan I.A., Imran A., Orhan I.E., Rizwan M., Atif M., et al. Luteolin, a flavonoid, as an anticancer agent: A review. Biomed. Pharmacother. 2019;112:108612. doi: 10.1016/j.biopha.2019.108612.", "ArticleIdList": ["10.1016/j.biopha.2019.108612", "30798142"]}, {"Citation": "Lin Y., Shi R., Wang X., Shen H.-M. Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy. Curr. Cancer Drug Targets. 2008;8:634\u2013646. doi: 10.2174/156800908786241050.", "ArticleIdList": ["10.2174/156800908786241050", "PMC2615542", "18991571"]}, {"Citation": "Bai L., Nong Y., Shi Y., Liu M., Yan L., Shang J., Huang F., Lin Y., Tang H. Luteolin Inhibits Hepatitis B Virus Replication through Extracellular Signal-Regulated Kinase-Mediated Down-Regulation of Hepatocyte Nuclear Factor 4\u03b1 Expression. Mol. Pharm. 2015;13:568\u2013577. doi: 10.1021/acs.molpharmaceut.5b00789.", "ArticleIdList": ["10.1021/acs.molpharmaceut.5b00789", "26656210"]}, {"Citation": "Fan W., Qian S., Qian P., Li X. Antiviral activity of luteolin against Japanese encephalitis virus. Virus Res. 2016;220:112\u2013116. doi: 10.1016/j.virusres.2016.04.021.", "ArticleIdList": ["10.1016/j.virusres.2016.04.021", "27126774"]}, {"Citation": "Yan H., Ma L., Wang H., Wu S., Huang H., Gu Z., Jiang J., Li Y. Luteolin decreases the yield of influenza A virus in vitro by interfering with the coat protein I complex expression. J. Nat. Med. 2019;73:487\u2013496. doi: 10.1007/s11418-019-01287-7.", "ArticleIdList": ["10.1007/s11418-019-01287-7", "30758716"]}, {"Citation": "Mehla R., Bivalkar-Mehla S., Chauhan A. A Flavonoid, Luteolin, Cripples HIV-1 by Abrogation of Tat Function. PLoS ONE. 2011;6:e27915. doi: 10.1371/journal.pone.0027915.", "ArticleIdList": ["10.1371/journal.pone.0027915", "PMC3227592", "22140483"]}, {"Citation": "Ueda H., Yamazaki C., Yamazaki M. Luteolin as an Anti-Inflammatory and Anti-Allergic Constituent of Perilla. Biol. Pharm. Bull. 2002;25:1197\u20131202. doi: 10.1248/bpb.25.1197.", "ArticleIdList": ["10.1248/bpb.25.1197", "12230117"]}, {"Citation": "Chen C.-Y., Peng W.-H., Tsai K.-D., Hsu S.-L. Luteolin suppresses inflammation-associated gene expression by blocking NF-\u03baB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci. 2007;81:1602\u20131614. doi: 10.1016/j.lfs.2007.09.028.", "ArticleIdList": ["10.1016/j.lfs.2007.09.028", "PMC7094354", "17977562"]}, {"Citation": "Franza L., Carusi V., Nucera E., Pandolfi F. Luteolin, inflammation and cancer: Special emphasis on gut microbiota. BioFactors. 2021;47:181\u2013189. doi: 10.1002/biof.1710.", "ArticleIdList": ["10.1002/biof.1710", "33507594"]}, {"Citation": "Theoharides T.C. Luteolin as a therapeutic option for multiple sclerosis. J. Neuroinflamm. 2009;6:29. doi: 10.1186/1742-2094-6-29.", "ArticleIdList": ["10.1186/1742-2094-6-29", "PMC2768692", "19825165"]}, {"Citation": "Xia N., Chen G., Liu M., Ye X., Pan Y., Ge J., Mao Y., Wang H., Wang J., Xie S. Anti-inflammatory effects of luteolin on experimental autoimmune thyroiditis in mice. Exp. Ther. Med. 2016;12:4049\u20134054. doi: 10.3892/etm.2016.3854.", "ArticleIdList": ["10.3892/etm.2016.3854", "PMC5228320", "28101184"]}, {"Citation": "Zeino M., Saeed M.E.M., Kadioglu O., Efferth T. The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein\u2014a well-known, yet poorly understood drug transporter. Investig. New Drugs. 2014;32:618\u2013625. doi: 10.1007/s10637-014-0098-1.", "ArticleIdList": ["10.1007/s10637-014-0098-1", "24748336"]}, {"Citation": "Abdelfatah S., Berg A., B\u00f6ckers M., Efferth T. A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening. J. Adv. Res. 2019;16:145\u2013156. doi: 10.1016/j.jare.2018.10.002.", "ArticleIdList": ["10.1016/j.jare.2018.10.002", "PMC6412170", "30899597"]}, {"Citation": "Abdelfatah S., Fleischer E., Klinger A., Wong V.K.W., Efferth T. Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Investig. New Drugs. 2019;38:1\u20139. doi: 10.1007/s10637-019-00752-0.", "ArticleIdList": ["10.1007/s10637-019-00752-0", "30877426"]}, {"Citation": "Efferth T. Complex Interactions between Phytochemicals. The Multi-Target Therapeutic Concept of Phytotherapy. Curr. Drug Targets. 2011;12:122\u2013132. doi: 10.2174/138945011793591626.", "ArticleIdList": ["10.2174/138945011793591626", "20735354"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "2", "Day": "8"}, {"Year": "2022", "Month": "2", "Day": "24"}, {"Year": "2022", "Month": "2", "Day": "26"}, {"Year": "2022", "Month": "3", "Day": "26", "Hour": "1", "Minute": "8"}, {"Year": "2022", "Month": "3", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "27", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "3", "Day": "3"}], "PublicationStatus": "epublish", "ArticleIdList": ["35337106", "PMC8952009", "10.3390/ph15030308", "ph15030308"]}}], "PubmedBookArticle": []}